Journal of Clinical Oncology, Vol 15, 268-276, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials

BG Haffty, YH Son, R Papac, CT Sasaki, JB Weissberg, D Fischer, S Rockwell, AC Sartorelli and JJ Fischer
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520-8040, USA. bruce.haffty@yale.edu

PURPOSE: Two consecutive randomized trials were run at our institution using the bioreductive alkylating agent mitomycin as an adjunct to radiation therapy in an effort to improve outcome in patients with squamous cell carcinoma of the head and neck. METHODS: Between 1980 and 1992, two consecutive randomized trials using mitomycin (trial 1) and mitomycin with dicumarol (trial 2) as an adjunct to radiation therapy in patients with squamous cell carcinoma of the head and neck were conducted at our institution. The patients were stratified by intent of therapy, extent of disease, and primary tumor site. Within each strata, patients were randomized to receive radiation therapy with or without mitomycin (trial 1) or mitomycin/dicumarol (trial 2). RESULTS: A total of 203 patients were enrolled onto both trials, 195 of whom were eligible for analysis. Patients were equally balanced with respect to sex, age, extent of disease, primary site, radiation dose, and total duration of radiation treatment. Hematologic toxicities were more frequently noted in the drug-treated arms, but were acceptable with no drug-related treatment deaths. Nonhematologic toxicities were acceptable and not significantly different between the two arms. As of September 1995, with a median follow-up of 138 months, a statistically significant benefit occurred in the mitomycin arms with respect to cause-specific survival (0.74 +/- 0.05 v 0.51 +/- 0.05; P = .005), local recurrence-free survival (0.85 +/- 0.04 v 0.66 +/- 0.05; P = .002), and local regional recurrence-free survival (0.76 +/- 0.05 v 0.54 +/- 0.05; P = .003). No statistically significant difference in overall survival was obtained (0.48 +/- 0.05 mitomycin arms v 0.42 +/- 0.05 radiation alone). CONCLUSION: The bioreductive alkylating agent mitomycin is a safe and effective adjunct to radiation therapy in the treatment of squamous cell carcinoma of the head and neck. The statistically and clinically significant improvement in local regional relapse and cause-specific survival obtained support the use of mitomycin as an adjunct to radiation therapy in the management of squamous cell carcinoma of the head and neck.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Wouters, B. Pauwels, F. Lardon, and J. B. Vermorken Review: Implications of In Vitro Research on the Effect of Radiotherapy and Chemotherapy Under Hypoxic Conditions Oncologist, June 1, 2007; 12(6): 690 - 712. [Abstract] [Full Text] [PDF]

				M. Rastogi, M. Srivastava, K. S. Chufal, M. C. Pant, K. Srivastava, and M. B. Bhatt Mitomycin and Fluorouracil in Combination with Concomitant Radiotherapy: A Potentially Curable Approach for Locally Advanced Head and Neck Squamous Cell Carcinoma Jpn. J. Clin. Oncol., October 1, 2005; 35(10): 572 - 579. [Abstract] [Full Text] [PDF]

				K. T. Robbins, P. Kumar, J. Harris, T. McCulloch, A. Cmelak, R. Sofferman, P. Levine, R. Weisman, W. Wilson, E. Weymuller, et al. Supradose Intra-Arterial Cisplatin and Concurrent Radiation Therapy for the Treatment of Stage IV Head and Neck Squamous Cell Carcinoma Is Feasible and Efficacious in a Multi-Institutional Setting: Results of Radiation Therapy Oncology Group Trial 9615 J. Clin. Oncol., March 1, 2005; 23(7): 1447 - 1454. [Abstract] [Full Text] [PDF]

				V. Budach, M. Stuschke, W. Budach, M. Baumann, D. Geismar, G. Grabenbauer, I. Lammert, K. Jahnke, G. Stueben, T. Herrmann, et al. Hyperfractionated Accelerated Chemoradiation With Concurrent Fluorouracil-Mitomycin Is More Effective Than Dose-Escalated Hyperfractionated Accelerated Radiation Therapy Alone in Locally Advanced Head and Neck Cancer: Final Results of the Radiotherapy Cooperative Clinical Trials Group of the German Cancer Society 95-06 Prospective Randomized Trial J. Clin. Oncol., February 20, 2005; 23(6): 1125 - 1135. [Abstract] [Full Text] [PDF]

				H. A. Seow, M. F. Belcourt, P. G. Penketh, W. F. Hodnick, M. Tomasz, S. Rockwell, and A. C. Sartorelli Nuclear Localization of NADPH:Cytochrome c (P450) Reductase Enhances the Cytotoxicity of Mitomycin C to Chinese Hamster Ovary Cells Mol. Pharmacol., February 1, 2005; 67(2): 417 - 423. [Abstract] [Full Text] [PDF]

				A.S. Garden, J. Harris, E.E. Vokes, A.A. Forastiere, J.A. Ridge, C. Jones, E.M. Horwitz, B.S. Glisson, L. Nabell, J.S. Cooper, et al. Preliminary Results of Radiation Therapy Oncology Group 97-03: A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck J. Clin. Oncol., July 15, 2004; 22(14): 2856 - 2864. [Abstract] [Full Text] [PDF]

				B. W. Chang, D. H. Kim, D. P. Kowalski, J. A. Burleson, Y. H. Son, L. D. Wilson, and B. G. Haffty Prognostic Significance of Cyclooxygenase-2 in Oropharyngeal Squamous Cell Carcinoma Clin. Cancer Res., March 1, 2004; 10(5): 1678 - 1684. [Abstract] [Full Text] [PDF]

				J. Aguilar-Ponce, M. Granados-Garcia, V. Villavicencio, A. Poitevin-Chacon, D. Green, A. Duenas-Gonzalez, A. Herrera-Gomez, K. Luna-Ortiz, A. Alvarado, H. Martinez-Said, et al. Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck Ann. Onc., February 1, 2004; 15(2): 301 - 306. [Abstract] [Full Text] [PDF]

				K. M. Holtz, S. Rockwell, M. Tomasz, and A. C. Sartorelli Nuclear Overexpression of NADH:Cytochrome b5 Reductase Activity Increases the Cytotoxicity of Mitomycin C (MC) and the Total Number of MC-DNA Adducts in Chinese Hamster Ovary Cells J. Biol. Chem., February 7, 2003; 278(7): 5029 - 5034. [Abstract] [Full Text] [PDF]

				L. B. Harrison, M. Chadha, R. J. Hill, K. Hu, and D. Shasha Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes Oncologist, December 1, 2002; 7(6): 492 - 508. [Abstract] [Full Text] [PDF]

				A. J. Khan, B. L. King, B. D. Smith, G. L. Smith, M. P. DiGiovanna, D. Carter, and B. G. Haffty Characterization of the HER-2/neu Oncogene by Immunohistochemical and Fluorescence in Situ Hybridization Analysis in Oral and Oropharyngeal Squamous Cell Carcinoma Clin. Cancer Res., February 1, 2002; 8(2): 540 - 548. [Abstract] [Full Text] [PDF]

				B. D. Smith, G. L. Smith, D. Carter, M. P. DiGiovanna, K. M. Kasowitz, C. T. Sasaki, and B. G. Haffty Molecular Marker Expression in Oral and Oropharyngeal Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, July 1, 2001; 127(7): 780 - 785. [Abstract] [Full Text] [PDF]

				O Pradier, K Eberlein, E Weiss, M C Jackel, and C F Hess Radiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluorouracil for inoperable head and neck cancer Br. J. Radiol., April 1, 2001; 74(880): 368 - 374. [Abstract] [Full Text] [PDF]

				A. Eisbruch, D. S. Shewach, C. R. Bradford, J. F. Littles, T. N. Teknos, D. B. Chepeha, L. J. Marentette, J. E. Terrell, N. D. Hogikyan, L. A. Dawson, et al. Radiation Concurrent With Gemcitabine for Locally Advanced Head and Neck Cancer: A Phase I Trial and Intracellular Drug Incorporation Study J. Clin. Oncol., February 1, 2001; 19(3): 792 - 799. [Abstract] [Full Text] [PDF]

				L. B. Harrison, D. Shasha, C. White, and B. Ramdeen Radiotherapy-Associated Anemia: The Scope of the Problem Oncologist, June 1, 2000; 5(2008): 1 - 7. [Abstract] [Full Text] [PDF]

				B. D. Smith, G. L. Smith, D. Carter, C. T. Sasaki, and B. G. Haffty Prognostic Significance of Vascular Endothelial Growth Factor Protein Levels in Oral and Oropharyngeal Squamous Cell Carcinoma J. Clin. Oncol., May 10, 2000; 18(10): 2046 - 2052. [Abstract] [Full Text] [PDF]

				H. Stopper, S. O. Mueller, and W. K. Lutz Supra-additive genotoxicity of a combination of {gamma}-irradiation and ethyl methanesulfonate in mouse lymphoma L5178Y cells Mutagenesis, May 1, 2000; 15(3): 235 - 238. [Abstract] [Full Text] [PDF]

				E. E. Vokes, M. S. Kies, D. J. Haraf, K. Stenson, M. List, R. Humerickhouse, M. E. Dolan, H. Pelzer, L. Sulzen, M. E. Witt, et al. Concomitant Chemoradiotherapy as Primary Therapy for Locoregionally Advanced Head and Neck Cancer J. Clin. Oncol., April 1, 2000; 18(8): 1652 - 1661. [Abstract] [Full Text] [PDF]

				G. Calais, M. Alfonsi, E. Bardet, C. Sire, T. Germain, P. Bergerot, B. Rhein, J. Tortochaux, P. Oudinot, and P. Bertrand Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx Carcinoma J Natl Cancer Inst, December 15, 1999; 91(24): 2081 - 2086. [Abstract] [Full Text] [PDF]

				A. S. Garden, B. S. Glisson, K. K. Ang, W. H. Morrison, S. M. Lippman, R. M. Byers, F. Geara, G. L. Clayman, D. M. Shin, D. L. Callender, et al. Phase I/II Trial of Radiation With Chemotherapy ""Boost"" for Advanced Squamous Cell Carcinomas of the Head and Neck: Toxicities and Responses J. Clin. Oncol., August 1, 1999; 17(8): 2390 - 2390. [Abstract] [Full Text] [PDF]